Sirtex

Conference Supporter

Information

Sirtex Medical is a global healthcare business working to improve outcomes in people with cancer. Our current lead product is a targeted radiation therapy for liver cancer called SIR-Spheres® Y-90 resin microspheres. More than 100,000 doses have been supplied to treat patients with liver cancer at more than 1,300 medical centers in over 50 countries. Learn more at https://SirtexVirtualBooth-EMEA.com/

Disclaimer
SIR-Spheres® is a Registered Trademark of Sirtex SIR-Spheres Pty Ltd
Videos
https://youtu.be/rFKfpzASu2w
Survey
https://forms.office.com/Pages/ResponsePage.aspx?id=FV-uY4SQU0KCTmQO8EH2iImcve_tBxxJiDOBVbyQ6jNUQlQwSVU1REo1VFVVSjNUU0RJVDVVWUY5RC4u

Social media

Contact details

learn-emea@sirtex.com
https://www.sirtex.com/
33, Joseph-Schumpeter-Allee, 53227, Bonn, Nordrhein-Westfalen, Deutschland

Documents & Links

NASIR study leafletNivolumab following SIRT for patients with unresectable advanced hepatocellular carcinoma. A multicentre, open-label, single-arm, phase II study.
HCC Patient Selection GuidePotential place of SIR-Spheres® in the BCLC staging system
SIRT as treatment option BCLC APotential place of SIR-Spheres® in stage BCLC A patients
SIR-Spheres Product InformationWhat are SIR-Spheres and what is Selective Internal Radiation Therapy
Case Report: Bridging to transplantation with SIR-SpheresA patient underwent liver transplantation one-year after SIRT.
Case Report: Down-staging to resection with SIR-SpheresLong-term survival of a patient who did not respond to TACE and got treated with SIR-Spheres.
Case Report: Ablative SIRT in a patient with PVIComplete ablation of the target lesions in a patient with multifocal disease and PVI.
Case Report: SIRT Leading to ResectionSustained radiological and biological response to SIRT leading to resection of a large previously unresectable hepatocellular carcinoma.

Log in